NCT06050707View on ClinicalTrials.gov

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2028

Conditions
Anal Squamous Cell Carcinoma
Interventions
RADIATION

Radiotherapy - Low risk group

20 fractions completed in 4 weeks

RADIATION

Radiotherapy - Standard risk group

25 fractions completed in 5 weeks

RADIATION

Radiotherapy - Intermediate risk group

30 fractions completed in 6 weeks

RADIATION

Radiotherapy - High risk group

35 fractions completed in 7 weeks

Trial Locations (4)

3084

NOT_YET_RECRUITING

Austin Health, Heidelberg

15212

NOT_YET_RECRUITING

Allegheny Health Network, Pittsburgh

53226

NOT_YET_RECRUITING

Medical College of Wisconsin Cancer Center, Milwaukee

M5G 2C1

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

lead

University Health Network, Toronto

OTHER